In the development of therapeutic monoclonal antibodies (mAbs), it is crucial to select lead candidates with optimal biological and pharmaceutical properties.
Binding affinity is a significant factor to consider. However, relying solely on affinity can be problematic, as the highest affinity mAbs may not exhibit optimal activity. To ensure the best lead candidates, it is crucial to consider factors like specificity, selectivity and biological relevance.
Epitope binning studies streamline candidate screening by pooling similarly behaving mAbs for further investigation in the development process.
Download this whitepaper to learn more about:
- The value of classifying mAbs by their binding behavior and biological functions
- How to group mAbs based on similar epitope binding regions
- Versatile, high-throughput technology for quick and accurate epitope binning
duction The selection of lead candidates in the development of therapeutic monoclonal antibodies (mAbs) is a critical decision. Designing a mAb that exhibits all the desired biological and pharmaceutical properties is challenging, and therefore, this process is primarily empirical. Numerous analytical studies are performed to identify leads with desirable characteristics, and among them, the evaluation of binding affinity is considered a significant factor. However, relying solely on affinity to select antibodies can be problematic since the highest affinity mAbs may not necessarily exhibit optimal activity. Therefore, it is important to consider additional factors such as specificity, selectivity, and biological relevance to ensure the selection of the most promising lead candidates for further development. The classification of monoclonal antibodies (mAbs) based on their binding behavior can be a valuable tool for selecting promising candidates for further development. Such classification often involves grouping mAbs with similar epitope binding regions, which are known to share similar biological functions. These groups or "bins" can streamline the candidate screening and selection process by providing a pool of similarly behaving mAbs for further investigation. Epitope binning studies are commonly used to classify mAbs into these groups and involve pairwise testing of all mAbs against each other. A classical epitope binning assay typically involves first binding an antigen with the desired epitope to a mAb candidate. Then, a second mAb is added, and the results are interpreted based on whether binding occurs or not. If binding occurs, it is assumed that the second mAb targets a different epitope. Conversely, if binding is blocked, it suggests that the binding epitopes are the same or closely related. Overall, epitope binning studies can provide useful information for selecting and characterizing mAbs for therapeutic applications. Automated 32x32 Epitope Binning in a Single Assay Brian Zabel, Vydehi Kanneganti, Vivienne Lee, Indrani Chakraborty, Rich Wang White Paper Introduction The selection of lead candidates in the development of therapeutic monoclonal antibodies (mAbs) is a critical decision. Designing a mAb that exhibits all the desired biological and pharmaceutical properties is challenging, and therefore, this process is primarily empirical. Numerous analytical studies are performed to identify leads with desirable characteristics, and among them, the evaluation of binding affinity is considered a significant factor. However, relying solely on affinity to select antibodies can be problematic since the highest affinity mAbs may not necessarily exhibit optimal activity. Therefore, it is important to consider additional factors such as specificity, selectivity, and biological relevance to ensure the selection of the most promising lead candidates for further development. The classification of monoclonal antibodies (mAbs) based on their binding behavior can be a valuable tool for selecting promising candidates for further development. Such classification often involves grouping mAbs with similar epitope binding regions, which are known to share similar biological functions. These groups or "bins" can streamline the candidate screening and selection process by providing a pool of similarly behaving mAbs for further investigation. Epitope binning studies are commonly used to classify mAbs into these groups and involve pairwise testing of all mAbs against each other. A classical epitope binning assay typically involves first binding an antigen with the desired epitope to a mAb candidate. Then, a second mAb is added, and the results are interpreted based on whether binding occurs or not. If binding occurs, it is assumed that the second mAb targets a different epitope. Conversely, if binding is blocked, it suggests that the binding epitopes are the same or closely related. Overall, epitope binning studies can provide useful information for selecting and characterizing mAbs for therapeutic applications. Automated 32x32 Epitope Binning in a Single Assay B
